

Claims (amended claims, 10 November 2004)

1. A pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant and/or antisedimentation agent is xanthan gum.
2. The pharmaceutical composition of claim 1, wherein the antiflocculant and /or antisedimentation agent is a combination of xanthan gum and maltodextrin.
3. The pharmaceutical composition of claim 1 or 2 further comprising a buffering agent.
4. The pharmaceutical composition of claims 1 to 3 in a dried form.
5. The pharmaceutical composition of claims 1 to 3 in a freeze-dried form.
6. The pharmaceutical composition of claims 1 to 5, wherein the cell lysate is a keratinocyte cell lysate.
7. The pharmaceutical composition of claims 1 to 6, wherein said composition further comprises a pharmaceutically acceptable carrier/excipient/vehicle.
8. The pharmaceutical composition of claims 1 to 7 for the purpose of promoting wound healing, wherein said composition comprises a non-viable cell lysate and a pharmaceutically acceptable vehicle.
9. The pharmaceutical composition of claims 7 or 8, wherein said pharmaceutically acceptable vehicle is a dry powder, a suspension or a solution.
10. The pharmaceutical composition of claims 7 or 8 wherein said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix.
11. A process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture, wherein the antiflocculant/antisedimentation agent is xanthan gum.
12. A process of claim 11 wherein drying the cells is by freeze-drying.
13. A process of claims 11 or 12, wherein cell the lysate is a keratinocyte cell lysate.
14. A process of claims 11 to 13 wherein the antiflocculant and/or antisendimentation agent is a combination of xanthan gum and maltodextrin.
15. Use of the composition of claim 1 to 10 for the treatment of burn wounds or skin ulcers.

BEST AVAILABLE COPY